[Cost-effective PET scans in oncology].
The authors have reviewed the financial considerations of oncological FDG PET examinations by the guidelines of the Health Care Financing Administration (USA). By critical assessment of large number of clinical investigations, the cost-effectiveness of FDG PET scans has been confirmed in the following cases: differential diagnosis of solitary pulmonary nodule, diagnosis, staging and restaging of non-small cell lung cancer, colorectal cancer, malignant lymphomas, melanoma malignum, esophageal neoplasms and cancers of the head and neck. The role of this method in breast cancer is currently under intensive investigation. Due to the correct staging, PET examinations in these indications enable the clinicians to choose the optimal treatment ensuring the maximum probability of recovery and being cost-effective as unnecessary medical interventions become avoidable.
Kálvin
Beáta
B
Debreceni Egyetem, Orvos- és Egészségtudományi Centrum, PET Centrum, Debrecen. kalvin@pet.dote.hu
Fekésházy
Attila
A
Lengyel
Zsolt
Z
Szakáll
Szabolcs
S
Agoston
Péter
P
Lengyel
Erzsébet
E
Székely
Judit
J
Várady
Erika
E
Galuska
László
L
Trón
Lajos
L
Esik
Olga
O
D001943:Breast Neoplasms / Q000000981:diagnostic imaging; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging; D003362:Cost-Benefit Analysis; D003937:Diagnosis, Differential; D004938:Esophageal Neoplasms / Q000000981:diagnostic imaging; D005260:Female; D019788:Fluorodeoxyglucose F18; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging; D006801:Humans; D006814:Hungary; D008175:Lung Neoplasms / Q000000981:diagnostic imaging; D008223:Lymphoma / Q000000981:diagnostic imaging; D006278:Medicare; D008545:Melanoma / Q000000981:diagnostic imaging; D009367:Neoplasm Staging; D009369:Neoplasms / Q000000981:diagnostic imaging* / Q000191:economics*; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed / Q000191:economics* / Q000379:methods; D014481:United States
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18